{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:12:04Z","timestamp":1780920724486,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101132","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:02:48Z","timestamp":1770480168000},"page":"101132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Retrospective evaluation of the \"neutrophil-lymphocyte ratio\" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1584-1991","authenticated-orcid":false,"given":"Chiara","family":"Mattioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Olmetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-0297","authenticated-orcid":false,"given":"Marco","family":"Banini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Garlatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Del","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-7908","authenticated-orcid":false,"given":"Paolo","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-4874","authenticated-orcid":false,"given":"Sara","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Metro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-3136","authenticated-orcid":false,"given":"Francesco","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0292-340X","authenticated-orcid":false,"given":"Fausto","family":"Meriggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Chella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Zannori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Delmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-1972","authenticated-orcid":false,"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0419-4694","authenticated-orcid":false,"given":"Marianna","family":"Macerelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-7369","authenticated-orcid":false,"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolo","family":"D\u2019Arcangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Del Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lugini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":false,"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Vasile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Iannopollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Adriana","family":"Taveggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Quaquarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Editta","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ponzanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1963-2371","authenticated-orcid":false,"given":"Mariangela","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Cergnul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-8397","authenticated-orcid":false,"given":"Andrea","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Tartarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Inno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Favaretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-273X","authenticated-orcid":false,"given":"Marco","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1068-5958","authenticated-orcid":false,"given":"Alessio","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vieri","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101132_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"\u00abInflammation and cancer: triggers, mechanisms, and consequences\u00bb","volume":"51","author":"Greten e","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ctarc.2026.101132_bib0002","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.semcancer.2022.11.006","article-title":"\u00abThe role of stem cells in small-cell lung cancer: evidence from chemoresistance to immunotherapy\u00bb","volume":"87","author":"Guo","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ctarc.2026.101132_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684807","article-title":"\u00abThe regulatory network and potential role of LINC00973-miRNA-mRNA ceRNA in the progression of non-small-cell lung cancer\u00bb","volume":"12","author":"Guo","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101132_bib0004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10142-023-01155-4","article-title":"\u00abGlycolysis induces Th2 cell infiltration and significantly affects prognosis and immunotherapy response to lung adenocarcinoma\u00bb","volume":"23","author":"Zeng","year":"2023","journal-title":"Funct. Integr. Genomics"},{"issue":"Pt 2","key":"10.1016\/j.ctarc.2026.101132_bib0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2022.09.005","article-title":"\u00abUnraveling tumor microenvironment of small-cell lung cancer: implications for immunotherapy\u00bb","volume":"86","author":"Li e","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"7749","key":"10.1016\/j.ctarc.2026.101132_bib0006","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"\u00abNeoantigen-directed immune escape in lung cancer evolution\u00bb","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101132_bib0007","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"\u00abUnderstanding the tumor immune microenvironment (TIME) for effective therapy\u00bb","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101132_bib0008","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/biom13121803","article-title":"\u00abNeutrophil-to-lymphocyte ratio (NLR) in NSCLC, gastrointestinal, and other solid tumors: immunotherapy and beyond\u00bb","volume":"13","author":"Mosca","year":"2023","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101132_bib0009","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"\u00abPrognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis\u00bb","volume":"106","author":"Templeton","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101132_bib0010","first-page":"45","article-title":"\u00abEpidemiology of lung cancer\u00bb","volume":"25","author":"Thandra","year":"2021","journal-title":"Contemp. Oncol. Poznan Pol."},{"key":"10.1016\/j.ctarc.2026.101132_bib0011","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2019.02.009","article-title":"\u00abClinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1\/PD-L1 inhibitors\u00bb","volume":"130","author":"Jiang","year":"2019","journal-title":"Lung Cancer Amst. Neth."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101132_bib0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5582\/bst.2019.01279","article-title":"\u00abNeutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer\u00bb","volume":"14","author":"Petrova","year":"2020","journal-title":"Biosci. Trend."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101132_bib0013","doi-asserted-by":"crossref","first-page":"180","DOI":"10.14740\/wjon1069w","article-title":"\u00abNeutrophil-to-lymphocyte ratio predicts overall survival of advanced non-small cell lung cancer harboring mutant epidermal growth factor receptor\u00bb","volume":"8","author":"Minami","year":"2017","journal-title":"World J. Oncol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101132_bib0014","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"\u00abDurvalumab after chemoradiotherapy in stage III non-small-cell lung cancer\u00bb","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101132_bib0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12967-017-1326-1","article-title":"\u00abSystemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer\u00bb","volume":"15","author":"Tong","year":"2017","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101132_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22964","article-title":"\u00abSystemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab\u00bb","volume":"33","author":"Liu","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.ctarc.2026.101132_bib0017","doi-asserted-by":"crossref","first-page":"v473","DOI":"10.1093\/annonc\/mdx380.029","article-title":"\u00abThe lung immune prognostic index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients\u00bb","volume":"28","author":"Mezquita","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101132_bib0018","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"\u00abAssociation of the Lung Immune prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer\u00bb","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101132_bib0019","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/bjc.2012.292","article-title":"\u00abA derived neutrophil to lymphocyte ratio predicts survival in patients with cancer\u00bb","volume":"107","author":"Proctor","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101132_bib0020","doi-asserted-by":"crossref","first-page":"967","DOI":"10.21037\/tlcr.2020.04.14","article-title":"\u00abThe lung immune prognostic index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients\u00bb","volume":"9","author":"Aldea","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101132_bib0021","first-page":"21","article-title":"\u00abRecognizing prognostic and predictive biomarkers in the treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs)\u00bb","volume":"12","author":"Giustini e","year":"2021","journal-title":"Lung Cancer Auckl. NZ"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101132_bib0022","first-page":"483","article-title":"\u00abNeutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may aid in identifying patients with non-small cell lung cancer and predicting Tumor-Node-Metastasis stages\u00bb","volume":"16","author":"Xu","year":"2018","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101132_bib0023","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/0284186X.2018.1546057","article-title":"\u00abThe prognostic role of inflammation-scores on overall survival in lung cancer patients\u00bb","volume":"58","author":"Sandfeld-Paulsen","year":"2019","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"10.1016\/j.ctarc.2026.101132_bib0024","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.radonc.2021.12.016","article-title":"\u00abPre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab\u00bb","volume":"167","author":"Thor","year":"2022","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101132_bib0025","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13014-024-02553-z","article-title":"\u00abPrognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer\u00bb","volume":"19","author":"Colomb","year":"2024","journal-title":"Radiat. Oncol. Lond. Engl."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101132_bib0026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12885-017-3122-y","article-title":"\u00abRelationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer\u00bb","volume":"17","author":"Derman","year":"2017","journal-title":"BMC Cancer"},{"issue":"28","key":"10.1016\/j.ctarc.2026.101132_bib0027","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/1759-7714.15406","article-title":"\u00abImmune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 \u226550% metastatic non-small cell lung cancer receiving first-line immunotherapy\u00bb","volume":"15","author":"Zheng","year":"2024","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.ctarc.2026.101132_bib0028","article-title":"\u00abThe predictive value of pretreatment lactate dehydrogenase and derived neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer patients treated with PD-1\/PD-L1 inhibitors: a meta-analysis\u00bb","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101132_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049123","article-title":"\u00abPrognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis\u00bb","volume":"11","author":"Yang","year":"2021","journal-title":"BMJ Open."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101132_bib0030","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"\u00abAtezolizumab for first-line treatment of metastatic nonsquamous NSCLC\u00bb","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101132_bib0031","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers13051176","article-title":"\u00abValue of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line Atezolizumab combination therapy: subgroup analysis of the IMPOWER150 trial\u00bb","volume":"13","author":"Hopkins","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101132_bib0032","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/jamaoncol.2019.1747","article-title":"\u00abPrognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer\u00bb","volume":"5","author":"Kazandjian","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101132_bib0033","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000514443","article-title":"\u00abThe lung immune prognostic index may predict the efficacy of different treatments in patients with advanced NSCLC: a meta-analysis\u00bb","volume":"44","author":"Xie","year":"2021","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101132_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1173025","article-title":"\u00abOn-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer\u00bb","volume":"14","author":"Xiong","year":"2023","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101132_bib0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/atm.2019.08.116","article-title":"\u00abPrognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis\u00bb","volume":"7","author":"Wang","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101132_bib0036","article-title":"\u00abThe relationship between systemic immune inflammatory index and prognosis of patients with non-small cell lung cancer: a meta-analysis and systematic review\u00bb","volume":"9","author":"Huang","year":"2022","journal-title":"Front. Surg."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101132_bib0037","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.clon.2021.03.019","article-title":"\u00abNeutrophil-lymphocyte ratio and absolute lymphocyte count as prognostic markers in patients treated with curative-intent radiotherapy for non-small cell lung cancer\u00bb","volume":"33","author":"Punjabi","year":"2021","journal-title":"Clin. Oncol. R. Coll. Radiol. G. B."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101132_bib0038","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.21037\/jtd-21-1018","article-title":"\u00abPretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial\u00bb","volume":"13","author":"Biswas","year":"2021","journal-title":"J. Thorac. Dis."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101132_bib0039","doi-asserted-by":"crossref","first-page":"524","DOI":"10.6061\/clinics\/2015(07)10","article-title":"\u00abPrognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis\u00bb","volume":"70","author":"Yin","year":"2015","journal-title":"Clin. Sao Paulo Braz."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101132_bib0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/atm-20-6710","article-title":"\u00abSystemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer\u00bb","volume":"9","author":"Keit","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101132_bib0041","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon-2020-1272","article-title":"\u00abSystemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy\u00bb","volume":"17","author":"Huang","year":"2021","journal-title":"Future Oncol. Lond. Engl."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101132_bib0042","doi-asserted-by":"crossref","first-page":"LMT67","DOI":"10.2217\/lmt-2023-0010","article-title":"\u00abPrognostic significance of systemic immune inflammatory index in NSCLC: a meta-analysis\u00bb","volume":"13","author":"Chen","year":"2024","journal-title":"Lung Cancer Manag."},{"issue":"7203","key":"10.1016\/j.ctarc.2026.101132_bib0043","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"\u00abCancer-related inflammation\u00bb","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101132_bib0044","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"\u00abCancer-related inflammation and treatment effectiveness\u00bb","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:50:36Z","timestamp":1780919436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":44,"alternative-id":["S2468294226000432"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101132","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective evaluation of the \"neutrophil-lymphocyte ratio\" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101132"}}